Connor, Clark & Lunn Investment Management Ltd. Bei Gene, Ltd. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 302,999 shares of BGNE stock, worth $68.7 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

302,999

Previous 291,606 3.91%

Holding current value

$68.7 Million

Previous $66.1 Million 3.91%

% of portfolio

0.26%

Previous 0.31%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	N/A	11,393 Added 3.91%	302,999 $68.7 Million
Q1 2025 May 12, 2025	BUY	$175.1 - $226.71 $1.26 Million - $1.64 Million	7,212 Added 2.54%	291,606 $66.1 Million
Q4 2024 Feb 10, 2025	BUY	$174.72 - $246.04 $10.2 Million - $14.4 Million	58,540 Added 25.92%	284,394 $52.5 Million
Q3 2024 Nov 08, 2024	BUY	$143.93 - $224.51 $20 Million - $31.2 Million	138,978 Added 159.97%	225,854 $50.7 Million
Q2 2024 Aug 09, 2024	BUY	$129.52 - $174.32 $2.75 Million - $3.71 Million	21,260 Added 32.4%	86,876 $12.4 Million
Q1 2024 May 09, 2024	BUY	$141.8 - $181.47 $4.57 Million - $5.85 Million	32,252 Added 96.67%	65,616 $10.3 Million
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $4.9 Million - $6.22 Million	30,869 Added 1237.23%	33,364 $6.02 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $2.58 Million - $3.23 Million	-14,331 Reduced 85.17%	2,495 $448,000
Q2 2023 Aug 10, 2023	SELL	$178.3 - $266.78 $2.74 Million - $4.1 Million	-15,361 Reduced 47.72%	16,826 $3 Million
Q1 2023 May 09, 2023	SELL	$215.53 - $274.5 $4.04 Million - $5.15 Million	-18,758 Reduced 36.82%	32,187 $6.94 Million
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $3.13 Million - $5.71 Million	24,922 Added 95.77%	50,945 $11.2 Million
Q3 2022 Nov 10, 2022	BUY	$131.8 - $202.24 $2.43 Million - $3.72 Million	18,417 Added 242.14%	26,023 $3.51 Million
Q2 2022 Aug 05, 2022	BUY	$121.11 - $216.05 $359,333 - $641,020	2,967 Added 63.96%	7,606 $1.23 Million
Q1 2022 May 12, 2022	BUY	$146.52 - $269.56 $498,754 - $917,582	3,404 Added 275.63%	4,639 $875,000
Q4 2021 Feb 10, 2022	BUY	$248.56 - $389.34 $306,971 - $480,834	1,235 New	1,235 $335,000
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $2.04 Million - $2.99 Million	-7,833 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $1.73 Million - $2.48 Million	7,833 New	7,833 $2.02 Million

Others Institutions Holding BGNE

# of Institutions

288

Shares Held

36.2M

Call Options Held

111K

Put Options Held

112K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Bei Gene, Ltd. Transaction History